Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027960 (
mole
)
21,279
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A complete hydatidiform mole (CHM) is androgenetic in origin and characterized by enhanced trophoblastic proliferation and the absence of fetal tissue. In 15 to 20% of cases, CHMs are followed by malignant gestational trophoblastic neoplasms including choriocarcinoma. Aberrant genomic imprinting may be responsible for trophoblast hypertrophy in CHMs, but the detailed mechanisms are still elusive, partly due to the lack of suitable animal or in vitro models. We recently developed a culture system of human trophoblast stem (TS) cells. In this study, we apply this system to CHMs for a better understanding of their molecular pathology. CHM-derived TS cells, designated as TS
mole
cells, are morphologically similar to biparental TS (TS
bip
) cells and express TS-specific markers such as GATA3,
KRT7
, and TFAP2C. Interestingly, TS
mole
cells have a growth advantage over TS
bip
cells only after they reach confluence. We found that p57
KIP2
, a maternally expressed gene encoding a cyclin-dependent kinase inhibitor, is strongly induced by increased cell density in TS
bip
cells, but not in TS
mole
cells. Knockout and overexpression studies suggest that loss of p57
KIP2
expression would be the major cause of the reduced sensitivity to contact inhibition in CHMs. Our findings shed light on the molecular mechanism underlying the pathogenesis of CHMs and could have broad implications in tumorigenesis beyond CHMs because silencing of
p57
KIP2
is frequently observed in a variety of human tumors.
...
PMID:Loss of p57
KIP2
expression confers resistance to contact inhibition in human androgenetic trophoblast stem cells. 3179 81
